Stay informed about the latest research breakthroughs, clinical developments, and organizational milestones in our mission to combat Long COVID
We're proud to announce that the European Patent Office has granted patent approval for our EPI1 botanical formulation. This milestone validates our innovative approach to wellness support and expands our intellectual property protection across European markets.
Latest clinical observations demonstrate significant improvement in brain fog and cognitive symptoms among Long COVID patients.
Read MoreMilestone achievement as our immunomodulation platform reaches patients across multiple continents with positive outcomes.
Read MoreOur innovative immunomodulation technology now protected across major markets worldwide, enabling global expansion.
Read MoreRenowned specialists in infectious disease, immunology, and FDA regulatory affairs join our advisory committee.
Read MorePlans unveiled for state-of-the-art research facility to support local economy and healthcare innovation.
Read MoreGroundbreaking study validates our approach to targeting FAAH, MAGL, COX2, MAO-B, and TRPV1 pathways simultaneously.
Read More